Given the timing of the company's earnings call last week, investors might have expected phase II data with etrasimod in ulcerative colitis (UC) from Arena Pharmaceuticals Inc., but eagerly awaited results from the 157-patient phase experiment testing the oral sphingosine-1-phosphate (S1P) receptor modulator will not roll out until later this month.